TY  - CONF

T1  - Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

JO  - Blood

PY  - 2015/12/03

AU  - Ashcroft J

AU  - Cairns DA

AU  - Williams C

AU  - Hockaday A

AU  - Cavenagh JD

AU  - Snowden JA

AU  - Parrish C

AU  - Yong KL

AU  - Cavet J

AU  - Hunter H

AU  - Bird J et al

ED  - 

DO  - DOI: 10.1182/blood.v126.23.1981.1981

PB  - American Society of Hematology

VL  - 126

IS  - 23

SP  - 1981

EP  - 1981

Y2  - 2024/12/22

ER  -